Fresenius Medical Care Pilot Shown to Significantly Reduce Hospitalization Days and Rates among High-Risk Dialysis Patients
February 19 2015 - 7:00AM
Business Wire
Second phase of pilot expands to dialysis
clinics in six states
Fresenius Medical Care (NYSE: FMS), North America’s leading
provider of kidney care services, announced today that its Dialysis
Hospitalization Reduction (DHR) pilot has resulted in more than a
50 percent reduction in hospitalization rates, and a 50 percent
reduction in hospitalization days among patients at high risk for
hospitalization. The DHR pilot uses Fresenius Medical Care’s
proprietary High Risk for Hospitalization Predictive Model to
determine which of its dialysis patients stand the greatest risk of
needing hospital care as a result of their chronic illnesses and
co-morbidities. Once patients are identified, dedicated DHR care
teams within their Fresenius Medical Care North America (FMCNA)
clinic intervene, to learn and manage the patients’ specific care
needs and preserve their health to prevent them from needing
hospitalization.
“By identifying high risk patients in our clinics and their
particular vulnerabilities, the DHR pilot enables our care teams to
efficiently provide patients with customized care for problems that
might otherwise go undetected and untreated,” said Dr. Frank
Maddux, Chief Medical Officer, FMCNA.
Based on these successful clinical results, FMCNA intends to
expand the DHR pilot to include more patients in more states across
the country. Phase one of the pilot, which was conducted in five
clinics in two states, resulted in a 51 percent reduction in
hospitalization rates among high-risk patients over a six month
period and a 50 percent drop in hospitalization days during this
same period of time. Phase two of the pilot has expanded to 17
clinics in six states, and as the DHR process is refined, this
activity will be expanded in phase three to test deployment at
scale in additional clinics. FMCNA will review processes and
outcomes from the DHR pilot to determine how it might be
incorporated into its ongoing patient care.
About Fresenius Medical Care North
America
Fresenius Medical Care North America is the premier health care
company focused on providing the highest quality care to people
with end stage renal disease (ESRD).
Through our leading network of more than 2,150 dialysis
facilities, outpatient cardiac and vascular labs, and urgent care
centers, as well as the largest practice of hospitalist and
post-acute providers in the country, Fresenius Medical Care
provides integrated and coordinated health care services to
hundreds of thousands of patients in the United States, Mexico and
Canada. As the only vertically integrated renal company in the
world, we also provide specialty pharmacy and laboratory services,
as well as manufacture and distribute the most comprehensive line
of dialysis equipment, dialyzers and related disposable products
and renal pharmaceuticals.
Media contact:Fresenius Medical CareJon Stone, 781-699-9704
(o)781-392-4680 (cell)jonathan.d.stone@fmc-na.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024